Subject:
- Active Substance: Mosunetuzumab
- Name: Lunsumio®
- Therapeutic area: Follicular lymphoma (FL)
- Pharmaceutical company: Roche Pharma AG
Time table:
- Start: 01.07.2022
- Final decision by G-BA: 15.12.2022
Final decision:
- Hint for a non-quantifiable additional benefit